Clinical Trial Update: Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adverse events and changes in disease activity with oral Upadacitinib in adults with non-segmental vitiligo; the study completed and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-segmental Vitiligo

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Non-Segmental Vitiligo | Phase 2 | Status: COMPLETED | Results posted: 2024-10-08